RecruitingOsteo Arthritis Knee

Combined Use of PRP and Hyaluronic Acid for Infiltrative Treatment of Patients With Knee Osteoarthritis

Eligible age

40–75 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

"PRP+HA-23" is a double-blind randomized controlled clinical trial with 1:1:1 allocation. The objective of the study is to evaluate by a randomized controlled, double-blind clinical trial the efficacy and safety of viscosupplementation-associated PRP infiltration compared with PRP-only or HA-only infiltration for the treatment of patients with knee osteoarthritis.

Sponsor: Istituto Ortopedico Rizzoli

You may qualify if…

✓ 1. Male or female patients, aged 40 to 75 years;
✓ 2. Patients with symptomatic knee osteoarthritis (VAS pain score between ≥ 3 and ≤ 8);
✓ 3. Unilateral involvement of symptomatology;
✓ 4. Radiographic or MRI signs of degenerative pathology of knee cartilage (Kellgren-Lawrence grade 1-3);
✓ 5. Failure, defined as the persistence of symptomatology, after at least one course of conservative treatment (pharmacological, physiotherapeutic or infiltrative treatment);
✓ 6. Hemoglobin \> 11 g/dl; Platelet count \> 150,000 plt/mm3 (Recently performed CBC examination);
✓ 7. Ability and consent of patients to actively participate in clinical follow-up;
✓ 8. Signature of informed consent.

You may not qualify if…

✕ 1. Patients unable to express consent;
✕ 2. Patients undergoing intra-articular infiltration of other substance in the previous 6 months;
✕ 3. Patients undergoing knee surgery in the previous 12 months;
✕ 4. Patients with malignant neoplasms;
✕ 5. Patients with rheumatic diseases;
✕ 6. Patients with uncontrolled diabetes;
✕ 7. Patients with hematological diseases (coagulopathies);
✕ 8. Patients on anticoagulant-antiaggregant therapy that cannot be discontinued at the time of blood collection;

Source: ClinicalTrials.gov · NCT06685120 · last updated 2026-02-03